ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2059

The Efficacy of Clinical Guidelines in Promoting Co-Prescription of Bone Protection with Glucocorticoids Among Hospital Doctors Treating Inpatients

Leonard C. Harty1, James Clare2, Dylan Finnerty2, Susan Van Der Kamp2, Fionnuala Kennedy3, Malachi McKenna4 and Oliver M. FitzGerald1, 1Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 2Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, 3Pharmacy Department, St. Vincent's University Hospital, Dublin, Ireland, 4Department of Endocrinology & Metabolic Bone Disease, St. Vincent's University Hospital, Dublin, Ireland

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Bisphosphonates, glucocorticoids and osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Quality Measures and Innovations in Practice Management and Care Delivery

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Therapeutic glucocorticoids (GC) rapidly decrease bone mineral density, inducing a remodelling imbalance by promoting osteoclast differentiation and activation and by inhibiting oscteocytes. Current guidelines direct that bisphosphonates (BP’s) and elemental calcium (Ca++) with Vitamin D (Vit. D) should be given at initiation of GC therapy, as it is known that bone remodelling imbalance occurs early with steroid usage. We circulated these guidelines within our hospital after auditing the existing practice of the hospitals doctors and 1yr later we sought to measure the efficacy of our intervention by completing an audit loop.

Methods: A cross sectional audit was performed of all adult medical and surgical inpatients in a tertiary referral centre teaching hospital. Prescribed GC and  concurrent anti osteoporotic medication were noted. Subsequent to the initial audit, guidelines promoting the use of BP’s, Ca++ and Vit. D when prescribing GC’s were advertised on hospital notice boards, in hospital bulletins, hospital prescribing guidelines and on the hospital website. One year after promoting guidelines the audit loop was completed by performing a similar cross sectional audit.

Results:

All inpatient medical records (n=417) were reviewed in Jan 2010.  52% of the inpatients were female and 58% were older than 65. 66/417 (16%) inpatients had been prescribed GC’s. Ca++ with Vit. D was prescribed for 20% of patients on GC’s with 2% also receiving BP therapy. 3% of patients were also receiving-post menopausal hormone replacement therapy.

In Nov 2011 one year after guideline publication, all 452 inpatient medical records (n=452) were reviewed.  63% of the patients were female and 60% were older than 65. 55/452 (12%) inpatients were prescribed GC’s. Ca++ with Vit. D was prescribed for 55% of patients on systemic steroids with 20% also receiving BP therapy.

The resultant improvement in the co-prescription of Ca++ & Vit. D and BP’s with GC’s by the order of 2.35 and 10 respectively can be attributed in part to the circulation of hospital guidelines. However 45% of patients on systemic steroids continued to receive no bone protection and 80% received suboptimal bone protection from steroid induced osteoporosis.  

Conclusion: Publication and advertisement of current bone protection guidelines when prescribing systemic steroids resulted in a substantial but suboptimal improvement by hospital doctors in our hospital in the co-prescription of bone protecting drugs to prevent steroid induced osteoporosis. In this audit it appears that the majority of prescribers do recognise the necessity to protect bone health when a patient requires steroids. However a substantial number of patients did not receive any bone protection. It is our perception that many physicians are not aware that short courses of steroids reduce bone mineral density and therefore greater efforts must be made to enhance doctor awareness of the necessity for bone protection to be prescribed at initiation of systemic steroids.


Disclosure:

L. C. Harty,
None;

J. Clare,
None;

D. Finnerty,
None;

S. Van Der Kamp,
None;

F. Kennedy,
None;

M. McKenna,
None;

O. M. FitzGerald,

Abbott Laboratories Ireland, Bristol-Myers Squibb,

2,

Abbott Laboratories Ireland, UCB,

5,

Abbott Laboratories Ireland,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-efficacy-of-clinical-guidelines-in-promoting-co-prescription-of-bone-protection-with-glucocorticoids-among-hospital-doctors-treating-inpatients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology